Marko Damm

Marko Damm

Auto-generated profile, based on publicly available information

Marko Damm

Department of Internal Medicine I, University Hospital Halle, Martin-Luther-University Halle-Wittenberg

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Pancreatology
Verified
Journal Article
Closed access
MDMarko Damm
Marko Damm
MWMaximilian Weniger
Maximilian Weniger
AKAnna-Katharina Kölsch
Anna-Katharina Kölsch
CLChristopher Lampert
Christopher Lampert
GCGüralp O. Ceyhan
Güralp O. Ceyhan
JRJonas Rosendahl
Jonas Rosendahl

27 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MDMarko Damm
Marko Damm
LELjupcho Efremov
Ljupcho Efremov
BBBenedikt Birnbach
Benedikt Birnbach
GTGretel Terrero
Gretel Terrero
Jörg KleeffJörg Kleeff
Jörg Kleeff
SKSebastian Krug
Sebastian Krug
Therapy with gemcitabine and nab-paclitaxel (GNP) is the most commonly used palliative chemotherapy, but its advantage in the neoadjuvant setting remains unclear. Accordingly, our aim is to evaluate the impact of first-line neoadjuvant therapy with GNP in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC). A systematic search for published studies until August 2020 was performed. The primary endpoint included resection and R0 resection rates in the intention-to-treat population. Secondary endpoints were response rate, survival and toxicity. Among 21 studies, 950 patients who received neoadjuvant GNP were evaluated. Treatment with GNP resulted in surgical resection and R0 resection rates as follows: 49% (95% CI 30–68%) and 36% (95% CI 17–58%) for BRPC and 16% (95% CI 7–26%) and 11% (95% CI 5–19%) for LAPC, respectively. The objective response rates and the median overall survival (mOS) ranged from 0 to 67% and 12 to 30 months, respectively. Neutropenia (range 5–77%) and neuropathy (range 0–22%) were the most commonly reported grade 3 to 4 adverse events. Neoadjuvant chemotherapy with GNP can be performed safely and with valuable effects in patients with BRPC and LAPC. The utility of GNP in comparison to FOLFIRINOX in the neoadjuvant setting requires further investigation in prospective randomized trials.

21 November 2023 in United European Gastroenterology Journal
Verified
Journal Article
Open access
MDMarko Damm
Marko Damm
LELjupcho Efremov
Ljupcho Efremov
MJMustafa Jalal
Mustafa Jalal
NNNabeegh Nadeem
Nabeegh Nadeem
JDJohannes Dober
Johannes Dober
JRJonas Rosendahl
Jonas Rosendahl
Background: Parameters to adapt individual treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) are urgently needed. The present study aimed to evaluate body composition parameters as predictors of overall survival (OS) in PDAC patients.Methods: Measurements of body composition parameters were performed on computed tomography scans at diagnosis. Height‐standardized and Body Mass Index‐ and sex‐adjusted regression formulas deriving cut‐offs from a healthy population were used. The Kaplan‐Meier method with the log‐rank test was performed for survival analysis. Independent prognostic factors were identified with uni‐ and multivariable Cox regression analyses.Results: In total, 354 patients were analyzed. In a multivariable Cox model, besides tumor stage and resection status, only myosteatosis (HR 1.53; 95% CI 1.10–2.14, p = 0.01) was an independent prognostic factor of OS among body composition parameters. Subgroup analyses revealed that the prognostic impact of myosteatosis was higher in patients ≤68 years of age, with advanced tumor stages and patients without curative intended resection.Conclusions: The analysis of one of the largest Caucasian cohorts to date, demonstrated myosteatosis to be an independent prognostic factor of OS in PDAC. To improve outcomes, prospective trials aiming to investigate the utility of an early assessment of myosteatosis with subsequent intervention by dieticians, sports medicine physicians, and physiotherapists are warranted.

1 September 2020 in Pancreatology
Verified
Journal Article
Closed access
MWMaximilian Weniger
Maximilian Weniger
JMJohn Moir
John Moir
MDMarko Damm
Marko Damm
LMLaura Maggino
Laura Maggino
MKMaximilian Kordes
Maximilian Kordes
PMPatrick Michl
Patrick Michl

1 December 2020 in Surgical Oncology
Verified
Journal Article
Closed access
MWMaximilian Weniger
Maximilian Weniger
JMJohn Moir
John Moir
MDMarko Damm
Marko Damm
LMLaura Maggino
Laura Maggino
MKMaximilian Kordes
Maximilian Kordes
RCRichard Charnley
Richard Charnley

Verified
Journal Article
Open access
PDF file
SKSebastian Krug
Sebastian Krug
MDMarko Damm
Marko Damm
JGJakob Garbe
Jakob Garbe
SKSenta König
Senta König
RSRosa Lynn Schmitz
Rosa Lynn Schmitz
ARAnja Rinke
Anja Rinke
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-controlled trials and long-established chemotherapy approaches. In addition, peptide receptor radionuclide therapy (PRRT) was approved as a parallel approach for pancreatic neuroendocrine tumors (NET), in addition to small bowel NET, after the NETTER-1 trial. The current ESMO and NCCN guidelines attempted to describe treatment algorithms for pancreatic NET based on the current data. In our survey, we recorded therapy decisions for the first- until the third-line of therapy in German-speaking countries (Germany, Austria, and Switzerland) using fictional case reports and discussed these in the context of the current ESMO guidelines. Compared with the recommendations of the guidelines, PRRT was used more frequently and earlier. In patients with NET G1/G2 Ki-67 < 10%, the therapy algorithm consisting of somatostatin analogs (SSA)-PRRT-targeted therapy is a relevant approach. In clinical situations where chemotherapy is primarily used (remission pressure, Ki-67 > 10%), second-line PRRT was found acceptance and was often considered prior to targeted therapies. Despite the lack of prospective controlled trials, our study demonstrated the pivotal impact of PRRT. Therefore, further studies should compare PRRT with chemotherapy in pancreatic NETs in different clinical settings in first- and second-line approaches.